New investment in fragile skin protection system for clinical applications
17/05/2009
Investment in APA Parafricta continues to grow as the potential for clinical applications worldwide is recognised. In clinical tests, the Parafricta system has been shown to reverse the effects of pressure ulcers, commonly known as bed sores. Bed sores represent a significant and increasing cost to healthcare systems worldwide due to demographic trends in age, obesity and chronic illnesses. Products that can reduce the numbers of people developing pressure ulcers and help treat those with them are being seriously looked at by healthcare providers worldwide.
The latest company investing in APA Parafricta is INVISTA, a subsidiary of Koch Industries Inc. INVISTA, headquartered in Wichita, Kan., U.S., delivers exceptional value to its customers through technology innovations, market insights and a powerful portfolio of global trademarks including LYCRA® fibre, STAINMASTER® carpet, COOLMAX® fabric, ANTRON® fibre and CORDURA® fabric.
“INVISTA is focused on supporting the development of products that create long-term value for customers and society,” said Jeff Brown, vice president of INVISTA Performance Surfaces and Materials. “We believe Parafricta™ products offer an innovative and cost-effective solution to a problem that currently costs health care providers millions of pounds and negatively affects the quality of life of countless individuals.”
The investment will be used in projects to expand use of Parafricta™ fabric in clinical applications globally as well as helping to develop a portfolio of innovative products for the PfFragile Skin Protection System™.
Further details can be obtained from the website at www.parafricta.com. Cornish WebServices are providing APA Parafricta with Search Marketing services to help promote their patent-protected Pf Fragile Skin Protection System.
